Prognostic value of circulating tumor cells and immune-inflammatory cells in patients with renal cell carcinoma

Urol Oncol. 2022 Apr;40(4):167.e21-167.e32. doi: 10.1016/j.urolonc.2021.12.021. Epub 2022 Feb 23.

Abstract

Purpose: The relationships among circulating tumor cells (CTCs), inflammatory cells, and platelets in patients with renal cell carcinoma (RCC) are not transparent. We evaluated the correlations among CTCs, blood inflammatory cells, and platelets in patients with RCC and their prognostic value for metastasis-free survival.

Methods: CTC and typical tumor cell chip data were collected and analyzed by the GEO database. The baseline data, survival data, CTCs data, and blood test results were statistically analyzed.

Results: Bioinformatics analysis showed that the function of the differentially expressed genes between CTCs and normal tumor cells mainly involved platelets and immune inflammation. A total of 82 patients whose follow-up time was 3 to 68 months were included in the analysis. Clinical data of the patients confirmed that there is a correlation between platelets and mesenchymal CTCs. Simultaneously, there was a correlation between immune inflammatory cells and platelets. The univariate Cox proportional hazards model indicated that staging, mesenchymal CTCs, and the monocyte-to-neutrophil ratio (MNR) had prognostic value. The multivariate Cox proportional hazards model indicated that staging and the MNR had prognostic value and high accuracy.

Conclusions: Bioinformatics analysis showed that CTCs were related to platelets and immune-inflammatory cells. Furthermore, the clinical data confirmed that platelets were correlated with mesenchymal CTCs and immune-inflammatory cells in the blood. By using mesenchymal CTCs, the MNR, or staging respectively, it is possible to predict the risk of postoperative metastasis in RCC patients. As a compound prognostic factor, staging, and the MNR can provide more convenient and accurate condition monitoring.

Keywords: Bioinformatics; Circulating tumor cells; Immune-inflammatory cells; Metastasis-free survival; Prognosis; Renal cell carcinoma.

MeSH terms

  • Biomarkers, Tumor
  • Carcinoma, Renal Cell* / pathology
  • Female
  • Humans
  • Kidney Neoplasms* / pathology
  • Male
  • Neoplastic Cells, Circulating* / pathology
  • Prognosis

Substances

  • Biomarkers, Tumor